Lv1
38 积分 2025-05-07 加入
Hemophagocytic Lymphohistiocytosis
2个月前
已完结
Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2个月前
已关闭
Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
4个月前
已关闭
Tumour lysis syndrome: new therapeutic strategies and classification
4个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
4个月前
已完结
Role of procalcitonin, C reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults
4个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
4个月前
已完结
皖公网安备34019202002308
